AI medical imaging analysis company AIDOT Inc. (CEO Jaehoon Jung) announced that the Korean Intellectual Property Office has made the decision to register its patent for the "Otitis Media Diagnosis Support System and Method", which the company had filed for.
This patent applies AI-based image analysis technology to the diagnosis process of otitis media, enabling faster and more accurate diagnostic support.
The patented technology uses an AI inference engine to analyze tympanic membrane images captured by an otoscope camera, determining the presence of otitis media. Based on the diagnosis, the system provides integrated diagnostic support including: △normal/abnormal notification △recommendations for hospital visits △referrals for remote interpretation.
A distinguishing feature of this invention is its dynamic knowledge base structure, which continuously updates medical data related to the eardrum, thereby improving diagnostic accuracy.
The invention offers a process that is divided into user-specific (self-diagnosis support) and medical professional-specific (hospital diagnosis support) modes. In the personal mode, users can capture images of the ear canal with an otoscope camera, and the AI analyzes the tympanic membrane for abnormalities, recommending nearby hospitals if needed. In the medical professional mode, the system allows remote referrals based on detailed disease classifications such as △acute △exudative △chronic otitis media.
This makes practical diagnostic support possible not only in primary medical institutions but also in homes, public health centers, and medically underserved areas.
AIDOT’s patented technology incorporates convolutional neural network (CNN) and Transformer-based algorithms for precise lesion feature analysis in tympanic membrane images, and includes a secure data communication structure for transmitting captured images and diagnostic results to hospital servers.
This technology is expected to serve as a foundation for future non-face-to-face medical services, remote collaborative care, and expansion of AI-based ENT diagnostic platforms.
CEO Jaehoon Jung stated, “Otitis media is a condition where early diagnosis in infants and children is extremely important, but missing the optimal treatment window can lead to significant problems. Through this patent registration decision, AIDOT has been officially recognized for the technical originality and business scalability of its AI-based diagnostic support technology in the ENT field.”
The patent was filed domestically on December 20, 2023, underwent examination, and received the registration decision on January 5, 2026. AIDOT also plans to pursue PCT international application and to introduce the technology to overseas medical settings by entering the global market.
Hankyung TV / January 9, 2026 / Reporter Yang Jae-jun
